Современные подходы к фармакотерапии послеродовой депрессии

Полный текст:   Только для подписчиков

Рекомендуемое оформление библиографической ссылки:

Усеинова А.Н., Федорец А.В., Кутькина В.М., Шабалин П.Н., Заитова Р.Л., Эмирова Д.А. Современные подходы к фармакотерапии послеродовой депрессии // Российский психиатрический журнал. 2025. №3. С. 95-102.

Аннотация

В научном обзоре представлены данные о современных стандартах фармакотерапии, гормональном лечении и новых аналогах аллопрегнанолона, а также обсуждаются современные представления о патофизиологии послеродовой депрессии. Представлены результаты различных клинических испытаний, которые были отобраны в таких электронных информационных ресурсах, как библиотека Elsevier, PubMed, NCBI, Google Scholar, eLIBRARY. Все они подтвердили эффективность в смягчении симптомов послеродовой депрессии у аналогов аллопрегнанолона, что приводит к улучшению качества жизни матерей. Разработка новых антидепрессантов – аналогов аллопрегнанолона, регистрация и внедрение существующих, является многообещающим направлением в России.

Ключевые слова послеродовая депресси; аллопрегнанолон; нейроактивные стероиды; брексанолон; зуранолон

Литература

1. Liu X, Wang S, Wang G. Prevalence and Risk Factors of Postpartum Depression in Women: A Systematic Review and Meta-analysis. J Clin Nurs. 2022;31(19-20):2665–77. PMID: 34750904; DOI: 10.1111/jocn.16121 2. Makarova MA, Tikhonova YuG, Avdeeva TI, et al. [Postpartum depression – risk factors, clinical and treatment aspects]. Nevrologiya, neyropsikhiatriya, psikhosomatika [Neurology, neuropsychiatry, psychosomatics]. 2021;(4):75–80. (In Russ.) 3. Suri R, Stowe ZN, Cohen LS, et al. Prospective Longitudinal Study of Predictors of Postpartum-Onset Depression in Women With a History of Major Depressive Disorder. J Clin Psychiatry. 2017;78(8):1110–6. PMID: 28297589; DOI: 10.4088/JCP.15m10427 4. Slomian J, Honvo G, Emonts P, et al. Consequences of maternal postpartum depression: a systematic review of maternal and infant outcomes. Womens Health. 2019;15:1745506519844044. PMID: 31035856; DOI: 10.1177/1745506519844044 5. Drury SS, Scaramella L, Zeanah CH. The Neurobiological Impact of Postpartum Maternal Depression: Prevention and Intervention Approaches. Child Adolesc Psychiatr Clin N Am. 2016;25(2):179–200. PMID: 26980123; DOI: 10.1016/j.chc.2015.11.001 6. Kieviet N, de Jong F, Scheele F, et al. Use of antidepressants during pregnancy in the Netherlands: observational study into postpartum interventions. BMC Pregnancy Childbirth. 2017;17(1):23. PMID: 28077067; DOI: 10.1186/s12884-016-1184-5 7. Anderson PO. Antidepressants and Breastfeeding. Breastfeed Med. 2021;16(1):5–7. PMID: 33237799; DOI: 10.1089/bfm.2020.0350 8. Chibanda D, Shetty AK, Tshimanga M. Group problem-solving therapy for postnatal depression among HIV-positive and HIV-negative mothers in Zimbabwe. J Int Assoc Provid AIDS Care. 2014;13(4):335–41. PMID: 23881909; DOI: 10.1177/2325957413495564 9. Cuomo A, Maina G, Neal SM, et al. Using sertraline in postpartum and breastfeeding: balancing risks and benefits. Expert Opin Drug Saf. 2018;17(7):719–25. PMID: 29927667; DOI: 10.1080/14740338.2018.1491546 10. Uguz F, Sharma V. Mood stabilizers during breastfeeding: a systematic review of the recent literature. Bipolar Disord. 2016;18(4):325–33. PMID: 27297617; DOI: 10.1111/bdi.12398 11. Misri S, Swift E, Abizadeh J, et al. Overcoming functional impairment in postpartum depressed or anxious women: a pilot trial of desvenlafaxine with flexible dosing. Ther Adv Psychopharmacol. 2016;6(4):269–76. PMID: 27536346; DOI: 10.1177/2045125316656297 12. Gregoire AJ, Kumar R, Everitt B, et al. Transdermal oestrogen for treatment of severe postnatal depression. Lancet. 1996;347(9006):930–3. PMID: 8598756; DOI: 10.1016/s0140-6736(96)91414-2 13. Li HJ, Martinez PE, Li X, et al. Transdermal estradiol for postpartum depression: results from a pilot randomized, double-blind, placebo-controlled study. Arch Womens Ment Health. 2020;23(3):401–12. PMID: 31372757; DOI: 10.1007/s00737-019-00991-3 14. Kettunen P, Koistinen E, Hintikka J, et al. Oestrogen therapy for postpartum depression: efficacy and adverse effects. A double-blind, randomized, placebo-controlled pilot study. Nord J Psychiatry. 2022;76(5):348–57. PMID: 34533410; DOI: 10.1080/08039488.2021.1974556 15. Dennis CL, Ross LE, Herxheimer A. Oestrogens and progestins for preventing and treating postpartum depression. Cochrane Database Syst Rev. 2008;2008(4):CD001690. PMID: 18843619; DOI: 10.1002/14651858.CD001690.pub2 16. Singata-Madliki M, Hofmeyr GJ, Lawrie TA. The effect of depot medroxyprogesterone acetate on postnatal depression: a randomised controlled trial. J Fam Plann Reprod Health Care. 2016;42(3):171–6. PMID: 27030698; DOI: 10.1136/jfprhc-2015-101334 17. Pieh Holder KL. Contraception and Breastfeeding. Clin Obstet Gynecol. 2015;58(4):928–35. PMID: 26457854; DOI: 10.1097/GRF.0000000000000157 18. Stefaniak M, Dmoch-Gajzlerska E, Jankowska K, et al. Progesterone and Its Metabolites Play a Beneficial Role in Affect Regulation in the Female Brain. Pharmaceuticals (Basel). 2023;16(4):520. PMID: 37111278; DOI: 10.3390/ph16040520 19. Schock H, Zeleniuch-Jacquotte A, Lundin E, et al. Hormone concentrations throughout uncomplicated pregnancies: a longitudinal study. BMC Pregnancy Childbirth. 2016;16(1):146. PMID: 27377060; DOI: 10.1186/s12884-016-0937-5 20. McEvoy K, Payne JL, Osborne LM. Neuroactive Steroids and Perinatal Depression: a Review of Recent Literature. Curr Psychiatry Rep. 2018;20(9):78. PMID: 30094520; DOI: 10.1007/s11920-018-0937-4 21. Weingarten SJ, Osborne LM. Review of the Assessment and Management of Perinatal Mood and Anxiety Disorders. Focus (Am Psychiatr Publ). 2024;22(1):16–24. PMID: 38694149; DOI: 10.1176/appi.focus.20230023 22. Maguire J, McCormack C, Mitchell A, et al. Neurobiology of maternal mental illness. Handb Clin Neurol. 2020;171:97–116. PMID: 32736761; DOI: 10.1016/B978-0-444-64239-4.00005-9 23. Powell JG, Garland S, Preston K, Piszczatoski C. Brexanolone (Zulresso): Finally, an FDA-Approved Treatment for Postpartum Depression. Ann Pharmacother. 2020;54(2):157–63. PMID: 31476884; DOI: 10.1177/1060028019873320 24. Martinez Botella G, Salituro FG, Harrison BL, et al. Neuroactive Steroids. 2. 3α-Hydroxy-3β-methyl-21-(4-cyano-1H-pyrazol-1'-yl)-19-nor-5β-pregnan-20-one (SAGE-217): A Clinical Next Generation Neuroactive Steroid Positive Allosteric Modulator of the (γ-Aminobutyric Acid) A Receptor. J Med Chem. 2017;60(18):7810–9. PMID: 28753313; DOI: 10.1021/acs.jmedchem.7b00846 25. Deligiannidis KM, Meltzer-Brody S, Gunduz-Bruce H, et al. Effect of Zuranolone vs Placebo in Postpartum Depression: A Randomized Clinical Trial. JAMA Psychiatry. 2023;80(2):191. PMID: 34190962; DOI: 10.1001/jamapsychiatry.2022.4181 26. Deligiannidis KM, Meltzer-Brody S, Maximos B, et al. Zuranolone for the Treatment of Postpartum Depression. Am J Psychiatry. 2023;180(9):668–75. PMID: 37491938; DOI: 10.1176/appi.ajp.20220785 27. Deligiannidis KM, Bullock A, Nandy I, et al. Zuranolone Concentrations in the Breast Milk of Healthy, Lactating Individuals: Results From a Phase 1 Open-Label Study. J Clin Psychopharmacol. 2024;44(4):337–44. PMID: 38739007; DOI: 10.1097/JCP.0000000000001873 28. Hecking J, Davoudian PA, Wilkinson ST. Emerging Therapeutics Based on the Amino Acid Neurotransmitter System: An Update on the Pharmaceutical Pipeline for Mood Disorders. Chronic Stress (Thousand Oaks). 2021;5:24705470211020446. PMID: 34124495; DOI: 10.1177/24705470211020446 29. De SK. Ganaxolone: First FDA-approved Medicine for the Treatment of Seizures Associated with Cyclin-dependent Kinase-like 5 Deficiency Disorder. Curr Med Chem. 2024;31(4):388–92. PMID: 36959132; DOI: 10.2174/0929867330666230320123952 30. Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. Progress report on new antiepileptic drugs: A summary of the Thirteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIII). Epilepsia. 2017;58(2):181–221. PMID: 28111749; DOI: 10.1111/epi.13634 31. Marinus Pharmaceuticals 2023a. A clinical trial of intravenous (IV) ganaxolone in women with postpartum depression. National Library of Medicine (S). 2023. URL: https://clinicaltrials.gov/study/NCT03228394 (accessed on: 13.12.2024). 32. Marinus Pharmaceuticals 2023b. A clinical trial of oral ganaxolone in women with postpartum depression. National Library of Medicine (US). 2023. URL: https://clinicaltrials.gov/study/NCT03460756 (accessed on: 13.12.2024). 33. Cerne R, Lippa A, Poe MM, et al. GABAkines – Advances in the discovery, development, and commercialization of positive allosteric modulators of GABAA receptors. Pharmacol Ther. 2022;234:108035. PMID: 34793859; DOI: 10.1016/j.pharmthera.2021.108035 34. Gerbera Therapeutics Inc 2023. Nora 520. URL: https://www.gerberarx.com/en/product/detail/NORA520 (accessed on: 13.12.2024). 35. LYT-300. A range of neurological and neuropsychological conditions, including anxiety, mood disorders and Fragile X-associated Tremor/Ataxia Syndrome. PuretechHealth. URL: https://puretechhealth.com/programs/details/lyt-300 (accessed on: 13.12.2024). 36. Brii Biosciences Limited 2023b. Brii Biosciences announces top-line results from phase 1 study of BRII-296, A long-acting therapy in development for postpartum depression. PRNewswire. URL: https://www.prnewswire.com/news-releases/brii-biosciences-announces-top-line-results-from-phase-1-study-of-brii-296-a-long-acting-therapy-in-development-for-postpartum-depression-301632804.html (accessed on: 13.12.2024). 37. Carlson K, Mughal S, Azhar Y, et al. Postpartum Depression. StatPearls. 2024;12:1–7. PMID: 30085612 38. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5TR). 2022. American Psychiatric Association Publishing. 39. Chen G, Xu M, Chen Z, Yang F. Clinical applications of small-molecule GABAAR modulators for neurological disorders. Bioorg Chem. 2024;153:107983. PMID: 39581171; DOI: 10.1016/j.bioorg.2024.107983

Метрики статей

Загрузка метрик ...

Metrics powered by PLOS ALM